Jaguar Animal Health to Present at the Aegis Capital 2015 Growth Conference

Sigue a La Opinión en Facebook

SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”),
an animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, announced today that Lisa Conte, CEO, will present at the
upcoming Aegis Capital 2015 Growth Conference at the Encore at Wynn in
Las Vegas on Thursday, October 8, 2015 at 9:30 am PT.

The event will be available via live audio webcast and archived replay
on Jaguar’s investor
relations website
.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals. Canalevia is Jaguar’s
lead prescription drug product candidate for the treatment of various
forms of watery diarrhea in dogs. Neonorm Calf is the
Company’s lead non-prescription product. Canalevia is a canine-specific
formulation of crofelemer, an active pharmaceutical ingredient isolated
and purified from the Croton lechleri tree, which is sustainably
harvested. Neonorm is a standardized botanical extract
derived from the Croton lechleri tree. Canalevia and Neonorm
are distinct products that act at the same last step in a physiological
pathway generally present in mammals. Jaguar has filed nine
Investigational New Animal Drug applications, or INADs, with the U.S.
FDA and intends to develop species-specific formulations of Neonorm
in six additional target species, and formulations of Canalevia for
cats, horses and dogs.

For more information, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding Jaguar’s planned
development of formulations of Canalevia and Neonorm™. In
some cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or
other similar expressions. The forward-looking statements in this
release are only predictions. Jaguar has based these forward-looking
statements largely on its current expectations and projections about
future events. These forward-looking statements speak only as of the
date of this release and are subject to a number of risks, uncertainties
and assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of any
new information, future events, changed circumstances or otherwise.

Contacts

KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
Jaguar-JAGX